Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
- 25 May 2006
- journal article
- clinical trial
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 65 (12), 1631-1634
- https://doi.org/10.1136/ard.2006.052092
Abstract
To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice. A retrospective observational study of all patients with spondylarthropathy with at least one uveitis flare treated with anti-TNF in one centre (December 1997-December 2004). The number of uveitis flares per 100 patient-years was compared before and during anti-TNF treatment; each patient was his or her own control. The relative risk (RR) and the number needed to treat (NNT) were calculated. 46 patients with spondylarthropathy treated with anti-TNF drugs had at least one uveitis flare (33 treated with anti-TNF antibodies, infliximab or adalimumab, and 13 with soluble TNF receptor, etanercept). The mean age at first symptoms was 26 years, 71% were men. Patients were followed for 15.2 years (mean) before anti-TNF versus 1.2 years during anti-TNF treatment. The number of uveitis flares per 100 patient-years before and during anti-TNF were, respectively: for all anti-TNF treatments,-51.8 v 21.4 (p = 0.03), RR = 2.4, NNT = 3 (95% confidence interval (CI) 2 to 5); for soluble TNF receptor-54.6 v 58.5 (p = 0.92), RR = 0.9; and for anti-TNF antibodies-50.6 v 6.8 (p = 0.001), RR = 7.4, NNT = 2 (95% CI 2 to 5). Anti-TNF treatments were efficacious in decreasing the number of uveitis flares in patients with spondylarthropathy. Anti-TNF antibodies decreased the rate of uveitis flares, whereas soluble TNF receptor did not seem to decrease this rate. These results could have consequences for the choice of anti-TNF treatment in certain patients.Keywords
This publication has 15 references indexed in Scilit:
- Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanerceptArthritis & Rheumatism, 2005
- Development of Crohn's disease in a patient taking etanercept.2005
- Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to InfliximabThe American Journal of Gastroenterology, 2005
- TNF?? Inhibitors in the Treatment of Psoriasis and Psoriatic ArthritisBioDrugs, 2005
- Why do anti-tumor necrosis factor antibodies work in Crohn's disease?2004
- [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].2002
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialThe Lancet, 2002
- Effect of infliximab on threatening panuveitis in Behçet's diseaseThe Lancet, 2001
- Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical UveitisOphthalmic Research, 2001
- New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti–tumor necrosis factor therapyCurrent Opinion in Rheumatology, 2001